Inside the Inflamed Eye: A 2026 Review Explains How Autoimmune Uveitis Begins and How to Treat It
Uveitis describes a broad group of inflammatory conditions affecting the uvea, the middle layer of the eye made up of the iris, ciliary body, and choroid. A comprehensive review published in Frontiers in Medicine in March 2026 explains how these conditions develop at a molecular level and why treatment approaches need to be matched to the specific immune pathway involved. Uveitis accounts for as much as 10% of vision impairment in the United States and Europe, and its annual incidence ranges from 17 to 52 cases per 100,000 people. It most often strikes adults between the ages of 20 and 50, amplifying both its personal and economic toll.
What makes uveitis particularly complex is that the eye is not a passive bystander in the immune system. The eye possesses what scientists call "immune privilege," a layered set of protections designed to prevent inflammation from damaging the irreplaceable neural tissue inside. These protections include physical barriers like the blood-retinal barrier, locally immunosuppressive molecules in the aqueous humor, and a tolerance mechanism called anterior chamber-associated immune deviation (ACAID), through which eye-resident immune cells travel to the spleen to educate the immune system into tolerance rather than attack. When these protections fail, disease follows.
In autoimmune uveitis, genetic susceptibility plays a key role. Variants in HLA genes determine how efficiently the immune system recognizes and responds to self-tissue, and certain HLA types dramatically raise the risk of specific uveitis subtypes. HLA-B27 is associated with acute anterior uveitis in conditions like axial spondyloarthritis, while HLA-A29 carries one of the strongest known genetic associations for any inflammatory eye disease, raising the risk of birdshot chorioretinopathy by up to 224-fold. Once autoreactive T cells escape normal tolerance controls, they are primed in lymph nodes and then recruited to the eye, where they disrupt the blood-retinal barrier and trigger cytokine cascades driven by TNF-alpha, IL-6, and IL-1 beta. Retinal microglia and recruited macrophages sustain and amplify this inflammation once it starts.
The review identifies four main categories of uveitis beyond the autoimmune type. Autoinflammatory uveitis arises not from adaptive immune attacks on self-tissue but from dysregulated innate immune pathways, particularly excess IL-1 signaling. Infectious uveitis results from direct intraocular infection or reactivation of dormant pathogens such as herpes viruses or toxoplasmosis. Post-infectious inflammation may persist through antigen mimicry long after the pathogen is gone. Paraneoplastic uveitis, also called autoimmune retinopathy, occurs when an immune response against a tumor cross-reacts with proteins in the retina.
Treatment, the review argues, should be matched to these underlying mechanisms rather than applied uniformly. Corticosteroids remain first-line across most forms of non-infectious uveitis, but steroid-sparing agents that target TNF or IL-6 pathways are increasingly used for autoimmune disease, while IL-1 blockade is preferred in autoinflammatory forms. For infectious uveitis, antimicrobials must be used first, with anti-inflammatory therapy added under antimicrobial cover. Looking forward, one area of particular interest is tissue-resident memory T cells, which persist in the eye even after active inflammation resolves. These cells may be why some patients experience recurrent flares and represent a potential target for future therapies aimed not just at controlling acute inflammation but at preventing relapse.